June 18, 2008 - Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin’s lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)—the first radioimmunotherapy treatment approved for use by the FDA, said researchers at SNM’s 55th Annual Meeting.
PET imaging allows practitioners to identify patients who could be treated, predict how they would respond and identify relapses early in patients who have follicular lymphoma, a common type of slow-growing lymphoma.